- Home
- NBXG vs VIR Comparison
NBXG vs VIR Comparison
Compare NBXG & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- VIR
- Stock Information
- Founded
- NBXG 2021
- VIR 2016
- Country
- NBXG United States
- VIR United States
- Employees
- NBXG N/A
- VIR N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- NBXG Finance
- VIR Health Care
- Exchange
- NBXG Nasdaq
- VIR Nasdaq
- Market Cap
- NBXG 900.2M
- VIR 844.9M
- IPO Year
- NBXG N/A
- VIR 2019
- Fundamental
- Price
- NBXG $14.60
- VIR $5.13
- Analyst Decision
- NBXG
- VIR Strong Buy
- Analyst Count
- NBXG 0
- VIR 7
- Target Price
- NBXG N/A
- VIR $32.86
- AVG Volume (30 Days)
- NBXG 243.7K
- VIR 1.1M
- Earning Date
- NBXG 01-01-0001
- VIR 07-31-2025
- Dividend Yield
- NBXG 10.25%
- VIR N/A
- EPS Growth
- NBXG N/A
- VIR N/A
- EPS
- NBXG N/A
- VIR N/A
- Revenue
- NBXG N/A
- VIR $20,861,000.00
- Revenue This Year
- NBXG N/A
- VIR N/A
- Revenue Next Year
- NBXG N/A
- VIR N/A
- P/E Ratio
- NBXG N/A
- VIR N/A
- Revenue Growth
- NBXG N/A
- VIR N/A
- 52 Week Low
- NBXG $9.31
- VIR $4.32
- 52 Week High
- NBXG $12.23
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- NBXG 78.87
- VIR 48.62
- Support Level
- NBXG $13.53
- VIR $5.00
- Resistance Level
- NBXG $13.87
- VIR $5.35
- Average True Range (ATR)
- NBXG 0.20
- VIR 0.24
- MACD
- NBXG 0.04
- VIR 0.02
- Stochastic Oscillator
- NBXG 95.88
- VIR 31.21
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.